186 related articles for article (PubMed ID: 33208914)
1. ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.
Jentzsch M; Grimm J; Bill M; Brauer D; Backhaus D; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
Bone Marrow Transplant; 2021 Apr; 56(4):936-945. PubMed ID: 33208914
[TBL] [Abstract][Full Text] [Related]
2. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Hansen DK; Kim J; Thompson Z; Hussaini M; Nishihori T; Ahmad A; Elmariah H; Faramand R; Mishra A; Davila ML; Khimani F; Lazaryan A; Sallman D; Liu H; Perez LE; Fernandez H; Nieder ML; Lancet JE; Pidala JA; Anasetti C; Bejanyan N
Transplant Cell Ther; 2021 Mar; 27(3):256.e1-256.e7. PubMed ID: 33781526
[TBL] [Abstract][Full Text] [Related]
3. Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry.
Núñez-Torrón Stock C; Jiménez Chillón C; Martín Moro F; Marquet Palomanes J; Velázquez Kennedy K; Piris Villaespesa M; Roldán Santiago E; Rodríguez Martín E; Chinea Rodríguez A; García Gutiérrez V; Moreno Jiménez G; López Jiménez J; Herrera Puente P
Hematol Oncol; 2023 Oct; 41(4):753-761. PubMed ID: 37081742
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation.
Grimm J; Jentzsch M; Bill M; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
Blood Adv; 2020 Aug; 4(16):3864-3874. PubMed ID: 32810221
[TBL] [Abstract][Full Text] [Related]
5. A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older.
Backhaus D; Brauer D; Pointner R; Bischof L; Vucinic V; Franke GN; Niederwieser D; Platzbecker U; Jentzsch M; Schwind S
Bone Marrow Transplant; 2023 Jan; 58(1):30-38. PubMed ID: 36195769
[TBL] [Abstract][Full Text] [Related]
6. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
Oran B; Jimenez AM; De Lima M; Popat UR; Bassett R; Andersson B; Borthakur G; Bashir Q; Chen J; Ciurea SO; Jabbour E; Cortes J; Kebriaei P; Khouri IF; Qazilbash MH; Ravandi F; Rondon G; Lu X; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1405-1412. PubMed ID: 25840338
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation.
Jentzsch M; Bischof L; Ussmann J; Backhaus D; Brauer D; Metzeler KH; Merz M; Vucinic V; Franke GN; Herling M; Platzbecker U; Schwind S
Blood Cancer J; 2022 Dec; 12(12):170. PubMed ID: 36529759
[TBL] [Abstract][Full Text] [Related]
8. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system.
Zhang H; Zheng X; Guo W; Xia Y; Zhang R; Zhai W; Chen X; Ma Q; Yang D; Wei J; Pang A; He Y; Feng S; Wang J; Han M; Jiang E
Exp Hematol Oncol; 2024 Feb; 13(1):16. PubMed ID: 38360825
[TBL] [Abstract][Full Text] [Related]
10. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
[TBL] [Abstract][Full Text] [Related]
11. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic Hematopoietic Stem Cell Transplantation Improved Survival for Adult Core Binding Factor Acute Myelogenous Leukemia Patients with Intermediate- and Adverse-Risk Genetics in the 2017 European LeukemiaNet.
Wang T; Chen S; Chen J; Liu T; Zhang T; Qiu H; Sun A; Chen S; Wu D; Xu Y
Transplant Cell Ther; 2021 Feb; 27(2):173.e1-173.e9. PubMed ID: 33830030
[TBL] [Abstract][Full Text] [Related]
13. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia.
Fenwarth L; Thomas X; de Botton S; Duployez N; Bourhis JH; Lesieur A; Fortin G; Meslin PA; Yakoub-Agha I; Sujobert P; Dumas PY; Récher C; Lebon D; Berthon C; Michallet M; Pigneux A; Nguyen S; Chantepie S; Vey N; Raffoux E; Celli-Lebras K; Gardin C; Lambert J; Malfuson JV; Caillot D; Maury S; Ducourneau B; Turlure P; Lemasle E; Pautas C; Chevret S; Terré C; Boissel N; Socié G; Dombret H; Preudhomme C; Itzykson R
Blood; 2021 Jan; 137(4):524-532. PubMed ID: 32871585
[TBL] [Abstract][Full Text] [Related]
14. Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission.
Jentzsch M; Bischof L; Backhaus D; Brauer D; Schulz J; Franke GN; Vucinic V; Niederwieser D; Platzbecker U; Schwind S
Blood Adv; 2022 Aug; 6(15):4570-4580. PubMed ID: 35605254
[TBL] [Abstract][Full Text] [Related]
15. Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.
Song GY; Kim HJ; Kim T; Ahn SY; Jung SH; Kim M; Yang DH; Lee JJ; Kim MY; Cheong JW; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Park SK; Kim SH; Choi CK; Kim HJ; Ahn JS; Kim DDH
Sci Rep; 2024 Apr; 14(1):8517. PubMed ID: 38609396
[TBL] [Abstract][Full Text] [Related]
16. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Rausch C; Rothenberg-Thurley M; Dufour A; Schneider S; Gittinger H; Sauerland C; Görlich D; Krug U; Berdel WE; Woermann BJ; Hiddemann W; Braess J; von Bergwelt-Baildon M; Spiekermann K; Herold T; Metzeler KH
Leukemia; 2023 Jun; 37(6):1234-1244. PubMed ID: 37041198
[TBL] [Abstract][Full Text] [Related]
17. Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Meur GL; Plesa A; Larcher MV; Fossard G; Barraco F; Loron S; Balsat M; Ducastelle-Leprêtre S; Gilis L; Thomas X; Ghesquières H; Tigaud I; Hayette S; Huet S; Sujobert P; Renault M; Thérèse RM; Michallet M; Labussière-Wallet H; Heiblig M
Transplant Cell Ther; 2023 Jan; 29(1):38.e1-38.e9. PubMed ID: 36108977
[TBL] [Abstract][Full Text] [Related]
18. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?
Yoon JH; Kim HJ; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Biol Blood Marrow Transplant; 2014 Jan; 20(1):80-8. PubMed ID: 24149098
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
20. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
